INS and type 2 diabetes mellitus: The present analysis of pioglitazone treatment and risk of developing AD in patients with T2DM yielded two new key findings: the pioglitazone treatment was an independent predictive factor for the occurrence of AD and concomitant insulin treatment enhanced the risk of pioglitazone-related AD.